Nomura M, et al. - The efficacy and safety of concurrent immune checkpoint inhibitor therapy and radiotherapy (immunoradiotherapy) in patients with metastatic melanoma after progression on nivolumab was determined herein. Based on findings, it was concluded that concurrent immunoradiotherapy is an option for patients with metastatic melanoma after progression on nivolumab.